Prelude Therapeutics Incorporated · NASDAQ:PRLD
Soleus Capital Management, L.P. reported a 5.20% stake in Prelude Therapeutics Incorporated (Schedule 13G)
Event Apr 21, 2026 · Filed Jul 8, 2026
Soleus Capital Management, L.P. reported a 5.20% stake in Prelude Therapeutics Incorporated, 3,378,378 shares, as a passive investor on Apr 21, 2026. Filed Jul 8, 2026 (Schedule 13G).
- Stake
- 5.20%
- Shares
- 3,378,378
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 9 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Soleus Private Equity Fund III, L.P. | 1.00% | 675,676 |
| Soleus Private Equity GP III, LLC | 1.00% | 675,676 |
| Soleus PE GP III, LLC | 1.00% | 675,676 |
| Soleus Capital Master Fund, L.P. | 4.20% | 2,702,702 |
| Soleus Capital, LLC | 4.20% | 2,702,702 |
| Soleus Capital Group, LLC | 4.20% | 2,702,702 |
| Soleus Capital Management, L.P. | 5.20% | 3,378,378 |
| Soleus GP, LLC | 5.20% | 3,378,378 |
| Levy Guy | 5.20% | 3,378,378 |
Source
Related
- Prelude Therapeutics Incorporated
- Soleus Capital Management, L.P.
- Prelude Therapeutics Incorporated shareholders
- Form 4 · Shah Rajeev M. · Apr 28, 2026
- Schedule 13G · Ra Capital Management, L.P. · Apr 28, 2026
- Form 4 · Bonita David P · Apr 23, 2026
- Form 4 · OrbiMed Genesis GP LLC · Apr 23, 2026
- Schedule 13D/A · Orbimed Advisors LLC · Apr 23, 2026